Volume 7 Supplement 1
Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL)
© Uldrick et al; licensee BioMed Central Ltd. 2012
Published: 19 April 2012
AIDS-PCNSL is a rare EBV-associated B-cell neoplasm that continues to carry a poor prognosis, even in the highly active antiretroviral therapy (HAART) era. We hypothesized that overall survival (OS) is affected by prior diagnosis of central nervous system (CNS) infections as well as treatment approaches to both HIV and AIDS-PCNSL. We evaluated risk factors and temporal trends for OS in patients with AIDS-PCNSL.
Adults with AIDS-PCNSL were identified through a computer linkage that matched AIDS case diagnosed between 1990-2000 from the San Francisco adult AIDS case registry with the California Cancer Registry (1985-2002), with mortality follow-up through 12/31/2007. Patients with non-B-cell histology or history of systemic non-Hodkgin lymphoma diagnosed within 2 years prior to AIDS-PCNSL diagnosis were excluded. Prognostic factors evaluated include: diagnosis of CNS infection prior to AIDS-PCNSL, diagnosis of other common opportunistic infection (OI) prior to AIDS-PCNSL (pneumocystis pneumonia [PCP] or mycobacterium avium complex [MAI]), pathologic versus clinical diagnosis, receipt of cancer therapy, HAART prescribed prior to or within 30 days of AIDS-PCNSL diagnosis, and year of diagnosis (1990-1995, 1996-1998, 1999-2002). Survival analyses employed Kaplan-Meier methodology.
Prior diagnosis of CNS infection, HAART, and cancer treatment are strong predictors of OS. OS improved over time in these patients. Earlier diagnosis of AIDS-PCNSL and/or CNS infection, treatment of CNS infections, and cancer treatment that includes HAART and concomitant chemotherapy may increase AIDS-PCNSL survival. Prospective evaluation of curative-intent chemotherapy-based approaches to AIDS-PCNSL is urgently needed. Additional analyses are ongoing.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.